Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

1. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

2. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial Full Text available with Trip Pro

The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) Permalink Copy Page navigation Ann Fam Med Actions . 2020 Jan;18(1):42-49. doi: 10.1370/afm.2488. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial , , , , , , , Affiliations Expand Affiliations 1 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada scott.garrison@ualberta.ca. 2 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. 3 Department of Anesthesiology, Pharmacology

2020 EvidenceUpdates

3. Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic

Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic Publications approval reference: 001559 NHS England and NHS Improvement Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic 31 March 2020 Version 1 As healthcare professionals we all have general responsibilities in relation to coronavirus and for these we should seek and act (...) on national and local guidelines. We also have a specific responsibility to ensure that anticoagulant care continues with the minimum burden on the NHS. We must engage with management and clinical teams planning the local response in our hospitals and across primary care. Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS

2020 NHS England

4. Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin

Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin March 2020 Jump to Resources Share By reading this page you agree (...) to ACOG's Terms and Conditions. . Baxter Healthcare first reported to the U.S. Food and Drug Administration in November 2017 shortages of heparin sodium 2,000 international units/L in 0.9% weight/volume sodium chloride intravenous infusion, heparin sodium 2,000 USP units in 1,000 mL, and heparin sodium 1,000 USP units in 500 mL . The purpose of this practice advisory is to review options for anticoagulation in late gestation for practitioners in areas affected by a heparin shortage. In some cases

2020 American College of Obstetricians and Gynecologists

5. Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Full Text available with Trip Pro

Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Extrapolation of clinical trial results comparing warfarin and direct-acting oral anticoagulant (DOAC) users experiencing major hemorrhage to clinical care is challenging due to differences seen among non-randomized oral anticoagulant users, bleed location, and etiology. We hypothesized that inpatient all-cause-mortality among patients presenting with major hemorrhage (...) differed based on the home-administered anticoagulant medication class, DOAC versus warfarin.More than 1.5 million hospitalizations were screened and 3731 patients with major hemorrhage were identified in the REDS-III Recipient Database. Propensity score matching and stratification were used to account for potentially confounding factors.Inpatient all-cause-mortality was lower for DOAC (HR = 0.60, 95%CI 0.45-0.80, p = 0.0005) before accounting for confounding and competing events. Inpatient all-cause

2020 EvidenceUpdates

6. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis (Abstract)

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown.This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term (...) for dabigatran and rivaroxaban were limited to major bleeding events. Compared with no anticoagulants, apixaban and warfarin were not associated with a significant decrease in stroke and/or systemic thromboembolism (apixaban 5 mg, hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.30 to 1.17; apixaban 2.5 mg, HR: 1.00; 95% CI: 0.52 to 1.93; warfarin, HR: 0.91; 95% CI: 0.72 to 1.16). Apixaban 5 mg was associated with a significantly lower risk of mortality (vs. warfarin, HR: 0.65; 95% CI: 0.45 to 0.93

2020 EvidenceUpdates

7. High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants

High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants Prescrire IN ENGLISH - Spotlight ''High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants'', 1 February 2020 {1} {1} {1} | | > > > High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight In the February issue of Prescrire International - High thrombotic risk and antiphospholipid antibodies: avoid direct oral anticoagulants FREE DOWNLOAD In the Adverse Effects section this month: should patients taking a direct oral anticoagulant switch to a vitamin K agonist such as warfarin, in light of the French drug regulatory agency's recent advisory? Full text available for free download. Summary In mid-2019, the French drug regulatory agency, ANSM

2020 Prescrire

8. Kidney Pre-biopsy medication: Antiplatelet and anticoagulant agents

Kidney Pre-biopsy medication: Antiplatelet and anticoagulant agents ____________________________________________________________________________________________________________ Renal Biopsy - Desmopressin Acetate July 2018 Page 1 of 15 2. PRE – BIOPSY MEDICATION – ANTIPLATELET AND ANTICOAGULANT AGENTS Date written: March 2018 Authors: Emily See, Paul Champion de Crespigny, Pamela Lopez-Vargas, Talia Gutman, Karine Manera, Solomon Menahem, John Saunders, David Voss, Jeffrey Wong and Rob (...) (to prevent major bleeding) or 7 days (to prevent minor bleeding) prior to the renal biopsy (1C). c. We suggest the use of bridging anticoagulation in patients at highest risk for thromboembolism. This includes patients with a mechanical mitral valve, a mechanical aortic valve and additional stroke risk factors, antiphospholipid syndrome, an embolic event within the previous 3 months, atrial fibrillation (CHADS2 score 5 or 6), and a previous thromboembolic event with interruption of anticoagulation (2C

2020 KHA-CARI Guidelines

9. What is the appropriate anticoagulation for patients with antiphospholipid syndrome?

What is the appropriate anticoagulation for patients with antiphospholipid syndrome? Chiefs’ Inquiry Corner – 1/6/19 – Clinical Correlations Search Chiefs’ Inquiry Corner – 1/6/19 January 6, 2020 2 min read Direct oral anticoagulants (DOACs) have replaced warfarin for many indications because they are effective and easier to use. Antiphospholipid syndrome is a notable exception to this trend. In a trial of 120 high risk patients with antiphospholipid syndrome randomized to rivaroxaban versus

2020 Clinical Correlations

10. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation (Abstract)

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation Warfarin is prescribed to patients with atrial fibrillation (AF) for the prevention of cardioembolic complications. Whether warfarin adversely affects bone health is controversial. The availability of alternate direct oral anticoagulant (DOAC) options now make it possible to evaluate the comparative safety of warfarin in association with fracture risk.To test the hypothesis that, among patients (...) with nonvalvular AF, use of DOACs vs warfarin is associated with lower risk of incident fracture.This comparative effectiveness cohort study used the MarketScan administrative claims databases to identify patients with nonvalvular AF and who were prescribed oral anticoagulants from January 1, 2010, through September 30, 2015. To reduce confounding, patients were matched on age, sex, CHA2DS2-VASc (congestive heart failure, hypertension, age [>65 years = 1 point; >75 years = 2 points], diabetes, and previous

2019 EvidenceUpdates

11. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants (Abstract)

Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures.The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA (...) or direct oral anticoagulants (DOACs).Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint.Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI

2019 EvidenceUpdates

12. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke

Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Patent foramen ovale closure, antiplatelet therapy (...) or anticoagulation therapy alone for management of cryptogenic stroke Order Download: Key message We are constantly trying to make our products better. On this publication we have tried out a new presentation: Patent foramen ovale (PFO) represents an opening in the heart placing people at risk of ischemic stroke. This report evaluates catheter-based PFO closure as an alternative treatment to antiplatelet therapy or anticoagulation for patients with a PFO having suffered a stroke. Our findings: PFO closure plus

2019 Norwegian Institute of Public Health

13. What Is the Incidence of Intracranial Hemorrhage Among Anticoagulated Patients With Minor Head Trauma? Full Text available with Trip Pro

What Is the Incidence of Intracranial Hemorrhage Among Anticoagulated Patients With Minor Head Trauma? What Is the Incidence of Intracranial Hemorrhage Among Anticoagulated Patients With Minor Head Trauma? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 74, Issue 1, Pages 98–100 What Is the Incidence of Intracranial Hemorrhage Among Anticoagulated Patients With Minor Head Trauma? x Michael Gottlieb (...) , MD (EBEM Commentator) , x Somy M. Thottathil , MD (EBEM Commentator) , x Jacob P. Holton , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: | Publication History Published online: December 20, 2018 Expand all Collapse all Article Outline Take-Home Message Among anticoagulated patients presenting with minor head trauma, 9% may have an intracranial hemorrhage. Methods Data Sources PubMed, EMBASE, the Cochrane databases, and the Database

2019 Annals of Emergency Medicine Systematic Review Snapshots

14. Left atrial appendage occlusion (LAAO) in patients with atrial fibrillation who have contraindications to oral anticoagulation

Left atrial appendage occlusion (LAAO) in patients with atrial fibrillation who have contraindications to oral anticoagulation SHTG Advice | 1 SHTG Advice 06-19 August 2019 In response to an enquiry from the National Advisory Committee for Heart Disease Left atrial appendage occlusion (LAAO) in patients with atrial fibrillation who have contraindications to oral anticoagulation Advice for NHSScotland Left atrial appendage occlusion (LAAO) may be offered to patients with non-valvular atrial (...) fibrillation deemed to be at high risk of ischaemic stroke, who have absolute contraindications to oral anticoagulation with warfarin and direct oral anticoagulants. Prior to undergoing the LAAO procedure, an individual patient risk assessment must be carried out by a multidisciplinary team. The potential future benefits of LAAO, the risks associated with the procedure, and the need for long- term antiplatelet therapy, should be discussed with each patient prior to making a treatment decision. LAAO

2019 SHTG Advice Statements

15. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. (Abstract)

Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. Management of anticoagulants for patients undergoing polypectomy is still controversial. Cold snare polypectomy (CSP) is reported to cause less bleeding than hot snare polypectomy (HSP).To compare outcomes between continuous administration of anticoagulants (CA) with CSP (CA+CSP) and periprocedural heparin (...) bridging (HB) with HSP (HB+HSP) for subcentimeter colorectal polyps.Multicenter, parallel, noninferiority randomized controlled trial. (University Hospital Medical Information Network Clinical Trials Registry: UMIN000019355).30 Japanese institutions.Patients receiving anticoagulant therapy (warfarin or direct oral anticoagulants) who had at least 1 nonpedunculated subcentimeter colorectal polyp.Patients were randomly assigned to undergo HB+HSP or CA+CSP and followed up 28 days after polypectomy.The

2019 Annals of Internal Medicine Controlled trial quality: predicted high

16. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Full Text available with Trip Pro

Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical (...) Considerations - Journal of Vascular and Interventional Radiology Email/Username: Password: Remember me Available now: Use your SIR login to access JVIR. Search Terms Search within Search Share this page Access provided by Article in Press Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations Endorsed

2019 Society of Interventional Radiology

17. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves (Abstract)

Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves Current guidelines endorse the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). However, little is known about their safety and efficacy in valvular heart disease (VHD). Similarly, there is a paucity of data regarding NOACs use in patients with a bioprosthetic heart valve (BPHV). We, therefore, performed a network meta-analysis

2019 EvidenceUpdates

18. Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials. Full Text available with Trip Pro

Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials. Anticoagulation, reducing the risk of thromboembolic events in patients undergoing cardioversion, is a cornerstone of peri-cardioversion management in patients with atrial fibrillation. We aimed to analyse published data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients undergoing cardioversion. We performed a systematic review of randomized prospective clinical (...) ). The incidence rate of adverse events during DOAC treatment was found to be very similar to that observed with warfarin anticoagulation. In RCTs DOAC treatment in patients undergoing cardioversion appears to be effective and safe. However, because evidence in this clinical setting is still weak, observational reports could be useful in providing further data about peri-procedural outcomes.

2019 Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace Controlled trial quality: uncertain

19. Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation

Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation CUAJ • April 2019 • Volume 13, Issue 4 © 2019 Canadian Urological Association 105 CUA GUIDELINE Cite as: Can Urol Assoc J 2019;13(4):105-14. http://dx.doi.org/10.5489/cuaj.5828 Published online December 14, 2018 Supplementary material available at cuaj.ca Introduction Surgery exposes patients to a risk of venous thromboembo- lism (VTE) and bleeding. VTE includes deep vein thrombosis (...) - laxis are considered. The first is prophylaxis used for primary prevention VTE for patients undergoing surgery. The second is management of an anticoagulant or antiplatelet agent used for treatment or as a form of secondary prevention dur - ing the perioperative period. The CUA thromboprophylaxis guideline panel feels that it is important for urologists to be engaged in the discussion and management in each of these situations. The panel recognizes that in many clinical contexts, other specialists

2019 Canadian Urological Association

20. Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study (Abstract)

Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study  Atrial fibrillation (AF) is associated with dementia. Anticoagulation may modify this relationship, but it is unclear if this is due to stroke reduction alone. Age- and sex-matched individuals from the U.K. Clinical Practice Research Datalink (2008-2016) with and without an incident diagnosis of AF were followed for a new dementia diagnosis. We estimated adjusted hazard ratios (aHRs (...) ) for incident dementia diagnosis in the AF cohort, overall and stratified by anticoagulation status, using the matched non-AF cohorts as reference. We performed a sensitivity analysis excluding individuals with stroke/transient ischaemic attack (TIA) before the observation period. Over 193,082 person-years (mean follow-up 25.7 ± 0.1 months), 347/15,276 AF (2.3%) and 1,085/76,096 non-AF (1.4%) were newly diagnosed with dementia (aHR, 1.31, 95% confidence interval, 1.15-1.49). The AF group had more co

2019 EvidenceUpdates